| Q33193416 | A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line. |
| Q38295976 | A factor of inducing IgE from a filarial parasite is an agonist of human CD40. |
| Q48160439 | Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis |
| Q37873932 | Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. |
| Q74602347 | Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154 |
| Q36221538 | Anti-CD 40 monoclonal antibody. |
| Q35131181 | Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals |
| Q35788328 | Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions |
| Q40843103 | CD154 variant lacking tumor necrosis factor homologous domain inhibits cell surface expression of wild-type protein |
| Q40918159 | CD154 variants associated with hyper-IgM syndrome can form oligomers and trigger CD40-mediated signals |
| Q47572384 | CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4(+) T cell responses following DNA vaccination of outbred animals. |
| Q24299911 | CD40 Ligand Blocks Apoptosis Induced by Tumor Necrosis Factor α, Glucocorticoids, and Etoposide in Osteoblasts and the Osteocyte-Like Cell Line Murine Long Bone Osteocyte-Y4 |
| Q34980894 | CD40 and its viral mimic, LMP1: similar means to different ends |
| Q39311520 | CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway |
| Q34266298 | CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies |
| Q52666648 | CD40 ligand deficiency causes functional defects of peripheral neutrophils that are improved by exogenous IFN-γ. |
| Q39731032 | CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus |
| Q45857463 | CD40 ligand mutants responsible for X-linked hyper-IgM syndrome associate with wild type CD40 ligand |
| Q47873933 | CD40 ligand-dependent signaling of bovine B lymphocyte development and differentiation |
| Q35793488 | CD40 ligation induces tissue factor expression in human vascular smooth muscle cells |
| Q41134276 | CD40-CD40 ligand: a multifunctional receptor-ligand pair. |
| Q41788290 | CD40-CD40L interaction in immunity against protozoan infections |
| Q90669240 | CD40L Priming of Platelets via NF-κB Activation is CD40- and TAK1-Dependent |
| Q33814059 | CD40L and Its Receptors in Atherothrombosis-An Update |
| Q42811066 | CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells |
| Q28731004 | Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction |
| Q38628139 | Circulating CD40 and sCD40L Predict Changes in Renal Function in Subjects with Chronic Kidney Disease |
| Q57075392 | Clinical spectrum of X-linked hyper-IgM syndrome |
| Q27666816 | Crystallographic and Mutational Analysis of the CD40-CD154 Complex and Its Implications for Receptor Activation |
| Q73895290 | Determination of the frequency of HLA antibody secreting B-lymphocytes in alloantigen sensitized individuals |
| Q24563090 | Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells |
| Q33377577 | Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion |
| Q46953712 | Enhancement of binding activity of soluble human CD40 to CD40 ligand through incorporation of an isoleucine zipper motif |
| Q34517239 | Excess soluble CD40L contributes to blood brain barrier permeability in vivo: implications for HIV-associated neurocognitive disorders |
| Q36367835 | Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo |
| Q37374541 | Functional CD40 ligand is expressed by T cells in rheumatoid arthritis |
| Q36028683 | Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis |
| Q44459472 | Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells |
| Q40314779 | Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon |
| Q40916167 | Generation of a soluble recombinant trimeric form of bovine CD40L and its potential use as a vaccine adjuvant in cows |
| Q34134411 | HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients |
| Q51243205 | Help to go: T cells transfer CD40L to antigen-presenting B cells. |
| Q71973601 | Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes |
| Q41216181 | Human native soluble CD40L is a biologically active trimer, processed inside microsomes |
| Q43832218 | Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury |
| Q38287944 | Incorporation of native antibodies and Fc-fusion proteins on DNA nanostructures via a modular conjugation strategy. |
| Q36497627 | Increased synthesis of anti-tuberculous glycolipid immunoglobulin G (IgG) and IgA with cavity formation in patients with pulmonary tuberculosis |
| Q52031885 | Inhibition of a secondary human alloimmune response via the soluble active component of CD154 (CD40L) in severe combined immune-deficient mice engrafted with human lymphocytes. |
| Q37474929 | Molecular mechanism and function of CD40/CD40L engagement in the immune system. |
| Q43182095 | New frontiers for platelet CD154. |
| Q33183129 | Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. |
| Q45761014 | Production of canine soluble CD40 ligand to induce maturation of monocyte derived dendritic cells for cancer immunotherapy. |
| Q35913436 | Reduced pathology following infection with transgenic Leishmania major expressing murine CD40 ligand |
| Q28484266 | Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells |
| Q44522206 | Sequence context strongly modulates association of polar residues in transmembrane helices |
| Q47661976 | Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction |
| Q48784822 | Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies |
| Q35772650 | Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection |
| Q34778615 | Soluble CD40 ligand stimulates CD40-dependent activation of the β2 integrin Mac-1 and protein kinase C zeda (PKCζ) in neutrophils: implications for neutrophil-platelet interactions and neutrophil oxidative burst |
| Q42212835 | Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection. |
| Q50768820 | Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen. |
| Q35754623 | T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation |
| Q37433321 | TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? |
| Q35534271 | TNF superfamily protein-protein interactions: feasibility of small- molecule modulation |
| Q27010594 | Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation? |
| Q33711057 | The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells |
| Q40289291 | The immunohistology of CD40 in human oral epithelium in health and disease |
| Q36745762 | The promiscuous protein binding ability of erythrosine B studied by metachromasy (metachromasia). |
| Q33858548 | The soluble CD40 ligand sCD154 in systemic lupus erythematosus |
| Q39605867 | The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer |
| Q36316025 | Titratable Avidity Reduction Enhances Affinity Discrimination in Mammalian Cellular Selections of Yeast-Displayed Ligands |
| Q88922346 | Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions |
| Q40314864 | Transfection and ligation of CD40 in human oral keratinocytes affect proliferation, adhesion and migration but not apoptosis in vitro |
| Q40325737 | Transfection of CD40 in a human oral squamous cell carcinoma keratinocyte line upregulates immune potency and costimulatory molecules |
| Q41945771 | Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection |
| Q37828473 | Tuning of CD40-CD154 interactions in human B-lymphocyte activation: a broad array of in vitro models for a complex in vivo situation |
| Q28972255 | Update on the hyper immunoglobulin M syndromes |
| Q33883558 | VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth |
| Q28300434 | Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis |
| Q64960314 | [Platelets cytokines and their effects on platelet transfusion]. |